LB Pharmaceuticals Inc
LBRX· Nasdaq
LBRXLB Pharmaceuticals Inc
Filed Aug 11, 2026 · 10-Q · 42 days after period end · 0001193125-26-343490
| Metric | Q2 2026 | Q2 2025 | Q2 2024 |
|---|---|---|---|
| Net Income | -$51.60M | -$4.87M | -$27.63M |
| EPS Diluted | -$1.71 | -$13.58 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
LB Pharmaceuticals Inc · CIK 1691082 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 11, 2026 · 42 d after period end
